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Hepatotoxicity is a rare adverse reaction to clopi-
dogrel that can evolve to fulminant hepatitis if
the drug is not discontinued.
Case report
The thienopyridine derivative clopidogrel (CPG)
inhibits ADP-induced platelet activation. It is
rapidly hydrolysed in the liver via cytochrome
P450 enzymes, by an irreversible and NADPH-
dependent mechanism. Clopidogrel therapy is
indicated in the prevention of thrombotic events
in patients with acute coronary syndromes,
ischemic stroke and peripheral arterial disease or
after percutaneous stent placement.
1 Currently, it
is widely used with a low occurrence of adverse
side-effects.
2 Hepatotoxicity is extremely rare.
There are 10 cases of pure liver injury reported in
the literature,
3–7 with liver failure in only one,
3
and in two, liver injury was part of a systemic
inﬂammatory response syndrome.
8,9 We report
here the second case of clopidogre-associated
hepatitis with acute liver failure.
An 80-year-old woman with history of hyper-
tension, type 2 diabetes, heart failure and dysli-
pidaemia was on glibenclamide, furosemide,
isossorbide dinitrate, acetylsalicylic acid and
simvastatin for several years with no evidence
of adverse effects. More recently clopidogrel
was introduced following angioplasty and stent
placement for treatment of acute myocardial
infarction. The patient was not taking any over-
the-counter, herbal or alternative medicines.
Thirty days after starting clopidogrel she was
admitted to the hospital with a one-week
history of dyspnoea, orthopnoea, lower limb
oedema, nausea and vomiting. Physical exam
revealed inspiratory rales and ankle oedema.
Laboratory evaluation yielded the following
abnormal values: AST 110 U/L (normal range
[NR] 0–31 U/L); ALT 190 U/L( N R0 – 3 1U /L);
total serum bilirubin 1.7 mg/dL (NR
0.1–1.1 mg/dL); direct serum bilirubin 0.7 mg/
dL (NR 0–0.3 mg/dL), γ-glutamyltransferase
166U/L( N R5 – 3 6U /L); lactate dehydrogenase
707 U/L (NR 240–480 U/L). Serum albumin
levels and coagulation proﬁle were normal.
Therapy for congestive heart failure was
optimized with resolution of the oedema and
pulmonary stasis. Despite the improvement of
heart failure, there was worsening of liver
biochemical tests with AST 388 U/L; ALT 540
U/L; total serum bilirubin 3.5 mg/dL;
γ-glutamyltransferase 209 U/L; alkaline phos-
phatase 139 U/L (NR 35–100 U/L) and lactate
dehydrogenase 1412 U/L and development of
liver failure as shown by increased prothrombin
time (INR 1.6) and low levels of factor V (4%, NR
>5%). Clopidogrel was then stopped. Serology
for acute viral hepatitis was negative and there
was no history of alcohol intake. Blood and urine
cultures were also negative. Autoimmune hepatitis
was excluded based on negative antinuclear, anti-
neutrophil cytoplasmic, anti-mitochondria and
anti-smooth muscle antibodies. The abdominal
ultrasound and endoscopic retrograde cholangio-
pancreaticography showed no abnormalities.
Drug-induced liver disease with an hepatocellular
pattern was therefore diagnosed and clopidogrel
was considered the most probable causative drug
given the close temporal relationship between
therapy initiation and liver injury, exclusion of
alternative causes and liver function/biochemical
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1tests normalization 29 days after drug discontinu-
ation (Figure 1). Importantly, all the other drugs
were taken continuously for several years with no
record of adverse effects and moreover liver bio-
chemical tests were normal at the time of clopido-
grel initiation. The Clinical Diagnostic Scale for
Drug Induced Hepatotoxicity
10 was applied and
revealed a high probability diagnosis (score 16).
Despite the severity of the hepatic injury with
signs of liver failure, biopsy was not performed as
clopidogrel was the only imputable drug and in
view of the rapid improvement of liver biochemis-
try after clopidogrel withdrawal. Re-exposition to
the drug was not performed for ethical reasons.
Discussion
Clopidogrel is a widely used inhibitor of platelet
aggregation associated with a low occurrence of
adverse side-effects. The most frequent side-effects,
detected in clinical studies and during the post
commercialization experience, are haemorrhage,
diarrhoea, abdominal pain and dyspepsia.
2
Hepatitis and acute liver dysfunction associated
with clopidogrel are extremely rare considering
the widespread use of this drug worldwide.
The mechanism of clopidogrel hepatotoxicity is
still unclear but is more likely to be non-dose-
dependent, either by an hypersensitivity
immunological mechanism or by a metabolic idio-
syncratic process dependent upon individual
susceptibility.
The diagnosis of clopidogrel-associated hepa-
titis in the present case is strongly supported by
the close temporal relationship between therapy
initiation and liver injury, exclusion of alternative
causes, liver function normalization after drug
discontinuation and a high probability diagnosis
in a previously validated scale.
10
Only 12 cases of clopidogrel hepatotoxicity are
described in the literature.
3–9These include eight
men and four women, aged 56–89 years old, that
developed liver injury 4 days to 6 months after
clopidogrel intake. The pattern of liver injury
was mainly mixed hepatocelullar-cholestatic, but
hepatocellular liver injuryand systemic inﬂamma-
tory response syndrome with hepatic injury were
also observed. Our case has the particularity of
exhibiting liver failure documented by factor V
and prothrombin time alterations at the peak of
cytolytic lesion, in contrast with all cases pub-
lished before 2009. Interestingly, a recent case of
clopidogrel liver injury with liver failure and
fatal outcome was published.
3
Considering the widespread use of clopidogrel,
namely with new therapeutical targets, it is impor-
tant to promote increased awareness of clinicians
for this rare adverse liver reaction that can, in
extremely rare cases, evolve to fulminant hepatitis
if the drug is not discontinued at early stages of
liver injury.
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